Latest Release
Apr 27, 2023
EPS / Forecast
2.05 / 1.97
Revenue / Forecast
11.3B / 11.49B
Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Latest Release
Jul 27, 2023
EPS / Forecast
1.75 / 1.98
Revenue / Forecast
11.2B / 11.81B
Jul 27, 2023
EPS / Forecast
1.75 / 1.98
Revenue / Forecast
11.2B / 11.81B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
(Reuters) -Drugmaker Bristol Myers (NYSE:BMY) Squibb on Thursday said its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
The company said sales of Revlimid and fellow blood cancer drug Pomalyst were also hurt by an increase in patients receiving free drugs from its patient assistance foundation. It now expects 2023 revenue to fall by low-single-digit percentages, compared with its previous forecast of a 2% increase in revenue for the year.
It does not expect the increase in patients seeking free Revlimid and Pomalyst to continue to be a drag on sales next year, the company's executives said on a conference call.
Shares of the company fell around 3.4% to $61.25 in premarket trade.
Bristol Myers is in the midst of a leadership change, with CEO Giovanni Caforio expected to step down in November to be succeeded by Chief Operating Officer Christopher Boerner. Boerner will be under pressure to execute on the launch of new products as Revlimid, Eliquis and cancer immunotherapy Opdivo eventually face cheaper competition.
The company also announced plans to buy back $4 billion of its shares in the third quarter.
Revenue in the quarter fell to $11.23 billion from $11.89 billion a year earlier, missing analysts' average forecast of $11.8 billion.
Revlimid sales were $1.47 billion in the quarter, compared with analyst expectations of $1.67 billion, Bristol said. It cut its full-year sales forecast for the drug, which began facing generic competition in the United States last year, by $1 billion to around $5.5 billion.
Sales of Eliquis, which Bristol Myers shares with Pfizer Inc (NYSE:PFE), were $3.2 billion in the quarter, down 1% from last year, hurt by generic competition in Canada and the UK, and $200 million below analysts' forecasts.
Opdivo sales were $2.15 billion in the quarter, $150 million short of analyst estimates.
Bristol Myers said it earned $1.75 per share in the quarter, down from $1.93 a year ago and below analyst expectations of $1.96.
It cut its 2023 earnings-per-share forecast by 60 cents to a range of $7.35 to $7.65 a share. Analysts had expected the company to earn $7.99 a share for the year.
Shares of Bristol Myers closed at $63.41 on Wednesday, down about 12% this year, underperforming the NYSE Arca Pharmaceutical index, which is basically flat.
The company said sales of Revlimid and fellow blood cancer drug Pomalyst were also hurt by an increase in patients receiving free drugs from its patient assistance foundation. It now expects 2023 revenue to fall by low-single-digit percentages, compared with its previous forecast of a 2% increase in revenue for the year.
It does not expect the increase in patients seeking free Revlimid and Pomalyst to continue to be a drag on sales next year, the company's executives said on a conference call.
Shares of the company fell around 3.4% to $61.25 in premarket trade.
Bristol Myers is in the midst of a leadership change, with CEO Giovanni Caforio expected to step down in November to be succeeded by Chief Operating Officer Christopher Boerner. Boerner will be under pressure to execute on the launch of new products as Revlimid, Eliquis and cancer immunotherapy Opdivo eventually face cheaper competition.
The company also announced plans to buy back $4 billion of its shares in the third quarter.
Revenue in the quarter fell to $11.23 billion from $11.89 billion a year earlier, missing analysts' average forecast of $11.8 billion.
Revlimid sales were $1.47 billion in the quarter, compared with analyst expectations of $1.67 billion, Bristol said. It cut its full-year sales forecast for the drug, which began facing generic competition in the United States last year, by $1 billion to around $5.5 billion.
Sales of Eliquis, which Bristol Myers shares with Pfizer Inc (NYSE:PFE), were $3.2 billion in the quarter, down 1% from last year, hurt by generic competition in Canada and the UK, and $200 million below analysts' forecasts.
Opdivo sales were $2.15 billion in the quarter, $150 million short of analyst estimates.
Bristol Myers said it earned $1.75 per share in the quarter, down from $1.93 a year ago and below analyst expectations of $1.96.
It cut its 2023 earnings-per-share forecast by 60 cents to a range of $7.35 to $7.65 a share. Analysts had expected the company to earn $7.99 a share for the year.
Shares of Bristol Myers closed at $63.41 on Wednesday, down about 12% this year, underperforming the NYSE Arca Pharmaceutical index, which is basically flat.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
(Reuters) -Bristol Myers Squibb on Thursday said its second-quarter sales fell more than expected and cut its full-year forecasts as two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
The company said sales of Revlimid and another blood cancer drug Pomalyst were also hurt by an increase in patients receiving them at no cost through its patient assistance foundation. It now expects 2023 revenue to fall by low-single-digit percentages, compared with its previous forecast of a 2% increase in revenue for the year.
The New York-based drugmaker does not see the increase in patients seeking free Revlimid and Pomalyst as a drag on sales next year.
"We expect this issue to be limited to this year because we are seeing that the applications for free product from our patient assistance foundation ... are returning to normal," CEO Giovanni Caforio said in an interview.
Bristol shares were off 3.2% at $61.38.
Bristol Myers (NYSE:BMY) is in the midst of a leadership change. Caforio is expected to step down in November and be succeeded by Chief Operating Officer Christopher Boerner.
The new CEO will be under pressure to execute on the launch of new products as Revlimid, Eliquis and cancer immunotherapy Opdivo eventually face cheaper competition.
The company also announced plans to buy back $4 billion of its shares in the third quarter.
Revenue in the quarter fell to $11.23 billion from $11.89 billion a year earlier, missing analysts' average forecast of $11.8 billion, according to Refinitiv data.
Revlimid sales of $1.47 billion in the quarter fell short of analyst expectations of $1.67 billion. The company cut its full-year sales forecast for the drug, which began facing generic competition in the United States last year, by $1 billion to around $5.5 billion.
Sales of Eliquis, which Bristol Myers shares with Pfizer (NYSE:PFE) , were hurt by generic competition in Canada and the UK. They came in at $3.2 billion for the quarter, down 1% from last year and $200 million below analysts' forecasts.
Opdivo sales were $2.15 billion, $150 million short of analyst estimates.
Bristol Myers said it earned $1.75 per share in the quarter, well below analyst expectations of $1.96.
It cut its 2023 earnings forecast by 60 cents to a range of $7.35 to $7.65 a share. That put even the high end far below analysts' estimates of $7.99 a share for the year.
Separately, Bristol Myers in a filing on Thursday said it had settled lawsuits against rival AstraZeneca (NASDAQ:AZN) alleging patent infringement for two of its cancer drugs.
Bristol Myers, which is sharing the settlement with Japan's Ono Pharmaceutical Co and the Dana-Farber Cancer Institute in Boston, will receive about $418 million in the settlement.
The company said sales of Revlimid and another blood cancer drug Pomalyst were also hurt by an increase in patients receiving them at no cost through its patient assistance foundation. It now expects 2023 revenue to fall by low-single-digit percentages, compared with its previous forecast of a 2% increase in revenue for the year.
The New York-based drugmaker does not see the increase in patients seeking free Revlimid and Pomalyst as a drag on sales next year.
"We expect this issue to be limited to this year because we are seeing that the applications for free product from our patient assistance foundation ... are returning to normal," CEO Giovanni Caforio said in an interview.
Bristol shares were off 3.2% at $61.38.
Bristol Myers (NYSE:BMY) is in the midst of a leadership change. Caforio is expected to step down in November and be succeeded by Chief Operating Officer Christopher Boerner.
The new CEO will be under pressure to execute on the launch of new products as Revlimid, Eliquis and cancer immunotherapy Opdivo eventually face cheaper competition.
The company also announced plans to buy back $4 billion of its shares in the third quarter.
Revenue in the quarter fell to $11.23 billion from $11.89 billion a year earlier, missing analysts' average forecast of $11.8 billion, according to Refinitiv data.
Revlimid sales of $1.47 billion in the quarter fell short of analyst expectations of $1.67 billion. The company cut its full-year sales forecast for the drug, which began facing generic competition in the United States last year, by $1 billion to around $5.5 billion.
Sales of Eliquis, which Bristol Myers shares with Pfizer (NYSE:PFE) , were hurt by generic competition in Canada and the UK. They came in at $3.2 billion for the quarter, down 1% from last year and $200 million below analysts' forecasts.
Opdivo sales were $2.15 billion, $150 million short of analyst estimates.
Bristol Myers said it earned $1.75 per share in the quarter, well below analyst expectations of $1.96.
It cut its 2023 earnings forecast by 60 cents to a range of $7.35 to $7.65 a share. That put even the high end far below analysts' estimates of $7.99 a share for the year.
Separately, Bristol Myers in a filing on Thursday said it had settled lawsuits against rival AstraZeneca (NASDAQ:AZN) alleging patent infringement for two of its cancer drugs.
Bristol Myers, which is sharing the settlement with Japan's Ono Pharmaceutical Co and the Dana-Farber Cancer Institute in Boston, will receive about $418 million in the settlement.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Bristol Myers plans to double experimental treatments to expand research pipeline
(Reuters) - Bristol Myers (NYSE:BMY) Squibb said on Thursday it plans to double the number of treatments it is testing in clinical trials, with a focus on cell therapies, over the next 18 months, as it contends with increasing generic competition for two of its top-selling drugs.
The drugmaker, which currently has six candidates in trials, will advance six more in its research pipeline - including three cell therapies that target immune system disorders and different types of cancer.
The New York-based company has been pressured by declining demand for two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, which face generic competition.
Bristol and partner Pfizer (NYSE:PFE)'s blood thinner Eliquis was also on the list of 10 drugs that will be subject to the first-ever price negotiations by the U.S. Medicare health program.
The company recently received regulatory approval for a new cell therapy manufacturing facility in Devens, Massachusetts and Bristol said it will continue expanding its manufacturing capacity.
Bristol, which already has two approved cell therapies in the U.S., Breyanzi and Abecma, targeting different blood cancer indications, said it plans to continue development for treatment of other diseases such as lupus erythematosus and multiple sclerosis.
The drugmaker is hosting an R&D day on Thursday, where executives are expected to provide details of the company's research strategy.
(Reuters) - Bristol Myers (NYSE:BMY) Squibb said on Thursday it plans to double the number of treatments it is testing in clinical trials, with a focus on cell therapies, over the next 18 months, as it contends with increasing generic competition for two of its top-selling drugs.
The drugmaker, which currently has six candidates in trials, will advance six more in its research pipeline - including three cell therapies that target immune system disorders and different types of cancer.
The New York-based company has been pressured by declining demand for two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, which face generic competition.
Bristol and partner Pfizer (NYSE:PFE)'s blood thinner Eliquis was also on the list of 10 drugs that will be subject to the first-ever price negotiations by the U.S. Medicare health program.
The company recently received regulatory approval for a new cell therapy manufacturing facility in Devens, Massachusetts and Bristol said it will continue expanding its manufacturing capacity.
Bristol, which already has two approved cell therapies in the U.S., Breyanzi and Abecma, targeting different blood cancer indications, said it plans to continue development for treatment of other diseases such as lupus erythematosus and multiple sclerosis.
The drugmaker is hosting an R&D day on Thursday, where executives are expected to provide details of the company's research strategy.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
(Reuters) - Bristol-Myers Squibb (NYSE:BMY) is set to acquire cancer drugmaker Mirati Therapeutics (NASDAQ:MRTX) for $58 per share in cash, representing $4.8 billion equity value.
Bristol-Myers Squibb will finance the transaction with a combination of cash and debt.
The transaction is expected to be dilutive to Bristol-Myers Squibb's non-GAAP earnings per share by approximately 35 cents per share in the first 12 months after the transaction closes.
Bristol-Myers Squibb will finance the transaction with a combination of cash and debt.
The transaction is expected to be dilutive to Bristol-Myers Squibb's non-GAAP earnings per share by approximately 35 cents per share in the first 12 months after the transaction closes.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Kto jest online
Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 12 gości